|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Browse our Recommended Readings on thyroids, disinfecting shared mobile phones, using a multimodal multidisciplinary team to prevent falls, and more. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
The FDA has approved Fetzima (levomilnacipran), a once-daily serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder. The labeling includes a Boxed Warning regarding the risk of suicidal thoughts and behaviors. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Email this NursingCenter eNews to your colleagues and invite them to join now. They, too, will receive great content as well as free articles and discount offers available only to subscribers. Want to make sure that you keep receiving NursingCenter eNews? Be sure to add [email protected] to your address book! NursingCenter respects your privacy and will not share your information with other companies or organizations without your permission. View our Privacy Policy. If you no long wish to receive NursingCenter eNews, click on the "Unsubscribe" link above. Forgotten your username or password? Please contact Customer Service at [email protected]. http://www.nursingcenter.com |
---|